ArticleJACC. Basic to translational science2020
Development of Tissue Engineered Heart Valves for Percutaneous Transcatheter Delivery in a Fetal Ovine Model.
Article in JACC. Basic to translational science, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 23 citations in OpenAlex.
- Repaired tetralogy of Fallot across adulthood: from right ventricular remodelling to targeted intervention.Heart failure reviews · 2026Review
- Analysis of Energy and Pressure in the Sinus with Different Blood Pressures after Bioprosthetic Aortic Valve Replacement.Annals of biomedical engineering · 2024Article
- Recent advancements in polymeric heart valves: From basic research to clinical trials.Materials today. Bio · 2024Review
- Non-immune factors cause prolonged myofibroblast phenotype in implanted synthetic heart valve scaffolds.Applied materials today · 2024Article
- Development of Novel Sutureless Balloon Expandable Fetal Heart Valve Device Using Absorbable Polycaprolactone Leaflets.Annals of biomedical engineering · 2024Article
- Hemodynamics During Development and Postnatal Life.Advances in experimental medicine and biology · 2024Review
- Cardiac tissue engineering: an emerging approach to the treatment of heart failure.Frontiers in bioengineering and biotechnology · 2024Review
- Strategies for Development of Synthetic Heart Valve Tissue Engineering Scaffolds.Progress in materials science · 2023Article
- Fluid Mechanical Effects of Fetal Aortic Valvuloplasty for Cases of Critical Aortic Stenosis with Evolving Hypoplastic Left Heart Syndrome.Annals of biomedical engineering · 2023Article
- Fibrin gel enhanced trilayer structure in cell-cultured constructs.Biotechnology and bioengineering · 2023Article
- Implanted Tissue-Engineered Vascular Graft Cell Isolation with Single-Cell RNA Sequencing Analysis.Tissue engineering. Part C, Methods · 2023Article
- The Potential Role of Regenerative Medicine on the Future Management of Hypoplastic Left Heart Syndrome.Journal of cardiovascular development and disease · 2022Article
- Tissue engineering: Relevance to neonatal congenital heart disease.Seminars in fetal & neonatal medicine · 2022Review
- The Real Need for Regenerative Medicine in the Future of Congenital Heart Disease Treatment.Biomedicines · 2021Review
- Next-generation tissue-engineered heart valves with repair, remodelling and regeneration capacity.Nature reviews. Cardiology · 2021Review
- Minimally Invasive Delivery of Tissue Engineered Heart Valves to the Pulmonary Annulus.JACC. Basic to translational science · 2020Article
Corrections and comments
- Commented on by
Authors and funding
20 authors at 9 institutions in 1 country.
Funding
Abstract
This multidisciplinary work shows the feasibility of replacing the fetal pulmonary valve with a percutaneous, transcatheter, fully biodegradable tissue-engineered heart valve (TEHV), which was studied in vitro through accelerated degradation, mechanical, and hemodynamic testing and in vivo by implantation into a fetal lamb. The TEHV exhibited only trivial stenosis and regurgitation in vitro and no stenosis in vivo by echocardiogram. Following implantation, the fetus matured and was delivered at term. Replacing a stenotic fetal valve with a functional TEHV has the potential to interrupt the development of single-ventricle heart disease by restoring proper flow through the heart.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.